Nutra Pharma to Exhibit at the 12th IDGA Battlefield Healthcare Summit in Washington, D.C. (OTCBB:NPHC)

March 11, 2010
Nutra Pharma will be exhibiting its over-the-counter (OTC) and prescription pain relievers, Nyloxin OTC and Nyloxin Rx, at the 12th IDGA Battlefield Healthcare Summit from March 29th through March 31st in Washington, D.C.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be exhibiting its over-the-counter (OTC) and prescription pain relievers, Nyloxin OTC and Nyloxin Rx, at the 12th IDGA Battlefield Healthcare Summit in Washington, D.C. The IDGA Battlefield Healthcare Summit is considered one of the premier military healthcare conferences and the start to the IDGA’s Military Health Week.

“The IDGA Battlefield Healthcare Summit is one of the most highly regarded forums for discussing best practices and next generation combat medicine and rehabilitative care,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We believe this summit provides an excellent venue for introducing our Nyloxin branded pain relievers to the military healthcare community,” he concluded.

Nutra Pharma first introduced Nyloxin OTC in November 2009 as a treatment for moderate to severe (Stage 2) chronic pain. Nyloxin OTC will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additionally, the Company introduced Nyloxin Rx in October 2009 as a prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function.
Both Nyloxin OTC and Nyloxin Rx are manufactured by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, and do not rely on the use of opioids or acetaminophen for their pain relieving action. Undiscovered Equities is currently offering a trial subscription. For more information please call 1-800-404-8982 or visit our website at www.undiscoveredequities.com

Sincerely,

Kevin McKnight
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
1-800-404-8982
www.undiscoveredequities.com